ORIC manages and monitors externally funded research projects undertaken by the faculty of Shaheed Zulfiqar Ali Bhutto Medical University.
| # | Research Title | Funding Agency | Type | Principal Investigator | Grant Amount (PKR) | Approval | Status |
|---|---|---|---|---|---|---|---|
| 1 | A phase III randomized double blind, placebo controlled clinical trial in 18 years of age and above to determine the safety and efficcay of ZF2001. | Anhui Zhifei Longcom Bipharmaceutical Co., Ltd | International | Prof. Dr. Tanwir Khaliq | 70.1 Million | 2021 | Completed |
| 2 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk outpatients with Covid-19 | ATEA USA | International | Prof. Dr Tanwir Khaliq | 1.8 Million | 2023 | Completed |
| 3 | A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the effect of Bi-26 (strain of Bifidobacterium longum, B. infantis) supplementation versus placebo on weight gain in underweight infants | Gates & Melinda USA | International | Prof. Dr Tanwir Khaliq, Prof. Dr. Maqbool Hussain |
12.7 Million | 2023 | Completed |
| 4 | A prospective cohort study investigating maternal, pregnancy and neonatal outcomes for women and neonates infected with SARS-CoV-2 | World Health Organization (WHO), Geneva | International | Dr. Syeda Kiran Riaz | 37 Million | 2021 | Completed |
| 5 | A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer (Clinical trial of melanoma drug) | Biocad Biotechnology Company, Russia | International | Prof. Dr. Tanwir Khaliq Dr. Qasim M. Buttar |
10 Million | 2024 | Completed |
| 6 | A Randomized, Double-Blind Clinical Study of the Efficacy and Safety of BCD-201 (JSC BIOCAD) and Keytruda® in Patients with Unresectable or Metastatic Melanoma | Biocad Biotechnology Company, Russia. | International | Prof. Dr. Tanwir Khaliq Dr. Qasim M. Buttar |
23 Million | 2023 | In-process |
| 7 | A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of Monotherapy with BCD-264 and Darzalex® in Subjects with Relapsed and Refractory Multiple Myeloma (Clinical trial of melanoma drug) | Biocad Biotechnology Company, Russia | International | Prof. Dr. Tanwir Khaliq Dr. Qasim M. Buttar |
23 Million | 2024 | In-process |
| 8 | A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects with Advanced Melanoma of the Skin (Clinical trial of melanoma drug) | Biocad Biotechnology Company, Russia | International | Prof. Dr. Tanwir Khaliq Dr. Qasim M. Buttar |
23 Million | 2024 | In-process |
| 9 | Genetic Characterization of Cognaitive Disability in Pakistani Population | Funded by HEC Pakistan | Local | Prof. Dr Javed Akram | 8.6 Million | 2017 | completed |
| 10 | Molecular and Epidemiology determinants of Breast Cancer | Funded by HEC Pakistan | Local | Dr Asmat Ullah | 0.5 Million | 2020 | completed |
| 11 | Prevalence of TP53 germline mutations in Breast cancer affected patients of Pakistan | Funded by HEC Pakistan | Local | Dr Syeda Kiran Riaz | 0.5 Million | 2020 | completed |
| 12 | Unraveling the genetic molecular landscape of high grade gliomas in Pakistani patients | Funded by HEC Pakistan | Local | Dr Saboora Waris | 0.5 Million | 2020 | completed |
| 13 | Application of Artificial Intelligence in Vascular Disease Management | National Centre for Artificial Intelligence (NCAI)-HEC, Pakistan | Local | Prof. Dr. Tanwir Khaliq | 10 Million | 2021 | Completed |
| 14 | Identification of molecular determinants of hereditary deafness. | Funded by PSF Pakistan | Local | Dr Mohsin Shahzad | 4.2 Million | 2016 | completed |
| 15 | Functional Characterization of two Novel Intellectual Disability genes, DCTN2 and METTL5. | Funded by HEC Pakistan | Local | Dr Mohsin Shahzad | 4.2 Million | 2019 | completed |
| 16 | Development of Artificial Intelligence based CADx system for rapid diagnosis of COVID-19 patients using Chest X-Ray (CXR) and Computed Tomography (CT) scans alongside RT-PCR | Funded by PSF Pakistan | Local | Prof. Dr Ayesha Isani Majeed | 19 milliom | 2019 | Completed |
| 17 | Genetic characterization of Prevalent Ophthalmic Disorders in Pakistan. | Funded by HEC Pakistan | Local | Dr. Waqar Arshad | 1.0 Million | 2021-22 | in process |
| 18 | Synthesis of Biowaste Derived Titania Nanoparticles and their Efficiency in Developing Novel Restorative Material for Dental Caries Treatment | NRPU-HEC | Local | Dr. Afsheen Mansoor | 9.87 Million | 2025 | In-process |
| 19 | Whole Exome Sequencing Services (Human Research Samples) | Molecular biology | Internal | Dr. Mohsin Shahzad | PKR 448,000 | in process | |
| 20 | THE GENETIC AND MOLECULAR BASIS OF INHERITED LENTICULAR DISORDERS. | PhD - Molecular biology | Internal | Dr. Muhammad Hassaan Ali (Supervisor: Dr. Tanveer Ahmed Qaiser) |
PKR 321,200 | in process | |
| 21 | UNDERSTANDING GENETIC CONTRIBUTIONS TO INFLAMMATORY RISK: A GWAS AND PRS STUDY OF C-REACTIVE PROTEIN. | M.Phil - Molecular biology | Internal | Ms. Anam Rasheed (Supervisor: Dr. Mohsin Shahzad) | PKR 530,700 | in process | |
| 22 | BIOINFORMATICS ANALYSIS OF GROWTH FACTOR HUB GENES IN DIMINISHED OVARIAN RESERVE-ASSOCIATED FOLLICULOGENESIS NETWORKS. | M.Phil - Molecular biology | Internal | Ms. Khushbakht Shoaib (Supervisor: Dr. Muhammad Rauf Ahmed) | PKR 297,000 | in process | |
| 23 | POLYGENIC RISK MODELING OF VITAMIN D DEFICIENCY: A GENOME-WIDE APPROACH FOR ASIAN POPULATIONS. | M.Phil - Molecular biology | Internal | Ms. Samra Noor (Supervisor: Dr. Tanveer Ahmed Qaiser) | PKR 405,900 | Completed | |
| 24 | GENOMIC INSIGHT INTO BONE FRAGILITY: GWAS AND POLYGENIC RISK PROFILING OF OSTEOPOROSIS. | M.Phil - Molecular biology | Internal | Ms. Samea Saboor (Supervisor: Dr. Tanveer Ahmed Qaiser) | PKR 405,900 | completed | |
| 25 | INVESTIGATING THE GENETIC UNDERPINNINGS OF SYNDROMIC DEAFNESS: A FOCUSED STUDY ON SELECTED FAMILIES. | M.Phil - Molecular biology | Internal | Ms. Atiqa Dar (Supervisor: Dr. Tanveer Ahmed Qaiser) | - | completed | |
| 26 | COMPARATIVE ANALYSIS OF GENETIC VARIANTS OF CASP8 AND TP53 IN BREAST CANCER PATIENTS IN PAKISTAN. | M.Phil - Molecular biology | Internal | Ms. Almas Asif (Supervisor: Dr. Syeda Kiran Riaz) | PKR 365,200 | completed | |
| 27 | GENETIC IDENTIFICATION OF AUTOSOMAL RECESSIVE ATAXIAS: INSIGHTS FROM THE PAKISTANI POPULATION | M.Phil - Molecular biology | Internal | Ms. Faiqa Batool (Supervisor: Dr. Mohsin Shahzad) | - | Completed | |
| 28 | COMPARATIVE ANALYSIS OF GENETIC VARIANTS OF TP53 RS1042522, RS587780728, AND RS201382018 IN BREAST CANCER PATIENTS IN PAKISTAN. | M.Phil - Molecular biology | Internal | Ms. Fazeela Tahir (Supervisor: Dr. Syeda Kiran Riaz) | PKR 378,400 | Completed | |
| 29 | OPTIMIZATION OF PCR-BASED GENETIC ASSAY FOR THE DIAGNOSIS OF HER2 POSITIVE BREAST CANCER PATIENTS. | M.Phil - Molecular biology | Internal | Mr. Yasir Rehman (Supervisor: Dr. Syeda Kiran Riaz) | PKR 665,500 | Completed | |
| 30 | THE MOLECULAR CHARACTERIZATION OF INHERITED DENTAL DISORDERS IN PAKISTANI POPULATION. | M.Phil - Molecular biology | Internal | Dr. Shafaq Maqsood (Supervisor: Dr. Mohsin Shahzad) | PKR 282,100 | Completed | |
| 31 | GENETIC ANALYSIS OF GENODERMATOSES IN PAKISTAN. | M.Phil - Molecular biology | Internal | Rimsha Khizar (Supervisor: Dr. Mohsin Shahzad) | PKR 282,100 | Completed | |
| 32 | GENETIC AND CLINICAL ANALYSIS OF CHRONIC KIDNEY DISEASE IN PAKISTANI POPULATION. | PhD - Molecular biology | Internal | Dr. Sohail Sabir (Supervisor: Dr. Mohsin Shahzad) | PKR 662,200 | Completed | |
| 33 | GENETICS CHARACTERIZATION OF ACHONDROPLASIA. | M.Phil - Molecular biology | Internal | Ms. Hira Ali (Supervisor: Dr. Tanveer Ahmed Qaiser) | PKR 237,100 | Completed | |
| 34 | CLINICAL SIGNIFICANCE OF MUCIN GENE FAMILY EXPRESSION IN RELATION TO TGF-B PATHWAY IN BREAST CANCER PATIENTS. | PhD - Molecular biology | Internal | Ms. Maham Noreena Nawaz (Supervisor: Dr. Syeda Kiran Riaz) | PKR 708,400 | Completed |